Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Dekeyne, A' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 26 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Millan, MJ; Brocco, M; Gobert, A; Dorey, G; Casara, P; Dekeyne, A
      Anxiolytic properties of the selective, non-peptidergic CRF1 antagonists, CP154,526 and DMP695: A comparison to other classes of anxiolytic agent

      NEUROPSYCHOPHARMACOLOGY
    2. Dekeyne, A; Rivet, JM; Gobert, A; Millan, MJ
      Generalization of serotonin (5-HT)(1A) agonists and the antipsychotics, clozapine, ziprasidone and S16924, but not haloperidol, to the discriminativestimuli elicited by PD128,907 and 7-OH-DPAT

      NEUROPHARMACOLOGY
    3. Millan, MJ; Dekeyne, A; Papp, M; La Rochelle, CD; Macsweeny, C; Peglion, JL; Brocco, M
      S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    4. Dekeyne, A; Gobert, A; Iob, L; Cistarelli, L; Melon, C; Millan, MJ
      Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats

      PSYCHOPHARMACOLOGY
    5. Dekeyne, A; Iob, L; Millan, MJ
      Following long-term training with citalopram, both mirtazapine and mianserin block its discriminative stimulus properties in rats

      PSYCHOPHARMACOLOGY
    6. Millan, MJ; Gobert, A; Rivet, JM; Adhumeau-Auclair, A; Cussac, D; Newman-Tancredi, A; Dekeyne, A; Nicolas, JP; Lejeune, F
      Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha(2)-adrenergic and serotonin(2C) receptors: a comparison with citalopram

      EUROPEAN JOURNAL OF NEUROSCIENCE
    7. Millan, MJ; Newman-Tancredi, A; Audinot, V; Cussac, D; Lejeune, F; Nicolas, JP; Coge, F; Galizzi, JP; Boutin, JA; Rivet, JM; Dekeyne, A; Gobert, A
      Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT1B, 5-HT1D and dopamine D-2 and D-3 receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states

      SYNAPSE
    8. Gobert, A; Dekeyne, A; Millan, MJ
      The ability of WAY100,635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224,289, but notBRL15572

      NEUROPHARMACOLOGY
    9. Dekeyne, A; Denorme, B; Monneyron, S; Millan, MJ
      Citalopram reduces social interaction in rats by activation of serotonin (5-HT)(2C) receptors

      NEUROPHARMACOLOGY
    10. Millan, MJ; Girardon, S; Monneyron, S; Dekeyne, A
      Discriminative stimulus properties of the dopamine D-3 receptor agonists, PD128,907 and 7-OH-DPAT: a comparative characterization with novel ligands at D-3 versus D-2 receptors

      NEUROPHARMACOLOGY
    11. Millan, MJ; Dekeyne, A; Newman-Tancredi, A; Cussac, D; Audinot, V; Milligan, G; Duqueyroix, D; Girardon, S; Mullot, J; Boutin, JA; Nicolas, JP; Renouard-Try, A; Lacoste, JM; Cordi, A
      S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    12. Millan, MJ; Lejeune, F; Gobert, A; Brocco, M; Auclair, A; Bosc, C; Rivet, JM; Lacoste, JM; Cordi, A; Dekeyne, A
      S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    13. Millan, MJ; Dekeyne, A; Rivet, JM; Dubuffet, T; Lavielle, G; Brocco, M
      S33084, a novel, potent, selective, and competitive antagonist at dopamineD-3-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    14. Millan, MJ; Brocco, M; Rivet, JM; Audinot, V; Newman-Tancredi, A; Maiofiss, L; Queriaux, S; Despaux, N; Peglion, JL; Dekeyne, A
      S18327 (1-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1) and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine,and 11 other antipsychotic agents

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    15. Dekeyne, A; Brocco, M; Adhumeau, A; Gobert, A; Millan, MJ
      The selective serotonin (5-HT)(1A) receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats - A comparison with other anxiolytic agents

      PSYCHOPHARMACOLOGY
    16. Millan, MJ; Gobert, A; Audinot, V; Dekeyne, A; Newman-Tancredi, A
      Inverse agonists and serotonergic transmission: From recombinant, human serotonin (5-HT)(1B) receptors to G-protein coupling and function in corticolimbic structures in vivo

      NEUROPSYCHOPHARMACOLOGY
    17. Dekeyne, A; Girardon, S; Millan, MJ
      Discriminative stimulus properties of the novel serotonin (5-HT)(2C) receptor agonist, RO 60-0175: a pharmacological analysis

      NEUROPHARMACOLOGY
    18. Millan, MJ; Schreiber, R; Monneyron, S; Denorme, B; Melon, C; Queriaux, S; Dekeyne, A
      S-16924, a novel, potential antipsychotic with marked serotonin(1A) agonist properties. IV. A drug discrimination comparison with clozapine

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    19. Millan, MJ; Brocco, M; Gobert, A; Schreiber, R; Dekeyne, A
      S-16924 [(R)-2-{1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl}1-(4-fluorophenyl)-ethanone], a novel, potential antipsychotic withmarked serotonin(1A) agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    20. Millan, MJ; Gobert, A; Girardon, S; Dekeyne, A
      Citalopram elicits a discriminative stimulus in rats at a dose selectivelyincreasing extracellular levels of serotonin vs. dopamine and noradrenaline

      EUROPEAN JOURNAL OF PHARMACOLOGY
    21. Millan, MJ; Girardon, S; Dekeyne, A
      5-HT2C receptors are involved in the discriminative stimulus effects of citalopram in rats

      PSYCHOPHARMACOLOGY
    22. MARINELLI M; BARROT M; SIMON H; OBERLANDER C; DEKEYNE A; LEMOAL M; PIAZZA PV
      PHARMACOLOGICAL STIMULI DECREASING NUCLEUS-ACCUMBENS DOPAMINE CAN ACTAS POSITIVE REINFORCERS BUT HAVE A LOW ADDICTIVE POTENTIAL

      European journal of neuroscience
    23. MILLAN MJ; DEKEYNE A; GOBERT A
      SEROTONIN (5-HT)(2C) RECEPTORS TONICALLY INHIBIT DOPAMINE (DA) AND NORADRENALINE (NA), BUT NOT 5-HT, RELEASE IN THE FRONTAL-CORTEX IN-VIVO

      Neuropharmacology
    24. MILLAN MJ; NEWMANTANCREDI A; BROCCO N; GOBERT A; LEJEUNE F; AUDINOT V; RIVET JM; SCHREIBER R; DEKEYNE A; SPEDDING M; NICOLAS JP; PEGLION JL
      S-18126 4-(2,3-DIHYDROBENZO[1,4]DIOXIN-6-YL)PIPERAZIN-1-YL METHYL]INDAN-2-YL)), A POTENT, SELECTIVE AND COMPETITIVE ANTAGONIST AT DOPAMINE D-4 RECEPTORS - AN IN-VITRO AND IN-VIVO COMPARISON WITH L-745,870 YL]PIPERAZIN-1-YL)METHYL-1H-PYRROLO[2,3B]PYRIDINE) AND RACLOPRIDE

      The Journal of pharmacology and experimental therapeutics
    25. AUDINOT V; NEWMANTANCREDI A; GOBERT A; RIVET JM; BROCCO M; LEJEUNE F; GLUCK L; DESPOSTE I; BERVOETS K; DEKEYNE A; MILLAN MJ
      A COMPARATIVE IN-VITRO AND IN-VIVO PHARMACOLOGICAL CHARACTERIZATION OF THE NOVEL DOPAMINE D-3 RECEPTOR ANTAGONISTS (-S-14297, NAFADOTRIDE, GR-103,691 AND U-99194())

      The Journal of pharmacology and experimental therapeutics
    26. MILLAN MJ; SCHREIBER R; DEKEYNE A; RIVET JM; BERVOETS K; MAVRIDIS M; SEBBAN C; MAURELREMY S; NEWMANTANCREDI A; SPEDDING M; MULLER O; LAVIELLE G; BROCCO M
      S-16924 YL]-PYRROLIDIN-3YL)-1-(4-FLUORO-PHENYL)-ETHANONE), A NOVEL, POTENTIAL ANTIPSYCHOTIC WITH MARKED SEROTONIN (5-HT)(1A) AGONIST PROPERTIES - II - FUNCTIONAL PROFILE IN COMPARISON TO CLOZAPINE AND HALOPERIDOL

      The Journal of pharmacology and experimental therapeutics


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/06/20 alle ore 14:46:34